Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07217678
PHASE4

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Sponsor: University of Miami

View on ClinicalTrials.gov

Summary

The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-02-09

Completion Date

2028-01-31

Last Updated

2026-03-05

Healthy Volunteers

No

Interventions

DRUG

Durysta, Bimatoprost Intracameral Implant 10 µg

Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg). Participants will be followed by a total of 3 months.

Locations (1)

Bascom Palmer Eye Institute

Miami, Florida, United States